TLSI (TriSalus Life Sciences, Inc.) Stock Financials & Earnings

TLSITriSalus Life Sciences, Inc.

Mkt Cap$175M

Healthcare·Medical - Devices·🇺🇸 United States·NASDAQ

Revenue (TTM)$45M

Net Income (TTM)-$39M

EPS (TTM)-$1.83

Free Cash Flow (TTM)-$19M

Gross Margin84.6%

Op. Margin-59.7%

Net Margin-86.9%

FCF Margin-41.9%

P/S Ratio (TTM)3.9x

P/E Ratio (TTM)—

YoY Rev Growth+53.4%

Employees—

Earnings Reports

Next: Q1 2026 · Apr 6

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$3M	$2M	-$10M
Q2 23	$5M	$4M	-$11M
Q3 23	$5M	$5M	-$19M
Q4 23	$6M	$5M	-$14M
Q1 24	$6M	$5M	-$12M
Q2 24	$7M	$6M	-$8M
Q3 24	$7M	$6M	-$9M
Q4 24	$8M	$7M	-$8M
Q1 25	$9M	$8M	-$7M
Q2 25	$11M	$9M	-$7M
Q3 25	$12M	$10M	-$9M
Q4 25	$13M	$11M	-$3M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 23	$6M	$4M	$3M
Q2 23	$7M	$5M	$3M
Q3 23	$10M	$9M	$5M
Q4 23	$8M	$6M	$6M
Q1 24	$6M	$5M	$7M
Q2 24	$5M	$4M	$6M
Q3 24	$4M	$5M	$6M
Q4 24	$3M	$5M	$7M
Q1 25	$3M	$5M	$7M
Q2 25	$4M	$6M	$7M
Q3 25	$5M	$7M	$7M
Q4 25	$3M	$4M	$8M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$7M	$0	$7M
Q2 23	$4M	$0	$4M
Q3 23	$21M	$0	$21M
Q4 23	$12M	$0	$12M
Q1 24	$4M	$0	$4M
Q2 24	$16M	$0	$16M
Q3 24	$11M	$0	$11M
Q4 24	$9M	$0	$9M
Q1 25	$13M	$0	$13M
Q2 25	$26M	$0	$26M
Q3 25	$23M	$0	$23M
Q4 25	$20M	$0	$20M

Shares Outstanding

Revenue Per Employee

Revenue / Employee